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Available online 27 September 2018Background: Antibodies targeting PD-1 and its ligand PDL1 are used in cancer immunotherapy but may lead to
autoimmune diseases, including type 1 diabetes (T1D). It remains unclear whether PDL1 is expressed in pancre-
atic islets of people with T1D and how is it regulated.
Methods: The expression of PDL1, IRF1, insulin and glucagon was evaluated in samples of T1D donors by immu-
noﬂuorescence. Cytokine-induced PDL1 expression in the human beta cell line, EndoC-βH1, and in primary
humanpancreatic isletswas determinedby real-timeRT-PCR,ﬂow cytometry andWestern blot. Speciﬁc andpre-
viously validated small interference RNAswere used to inhibit STAT1, STAT2, IRF1 and JAK1 signaling. Key results
were validated using the JAK inhibitor Ruxolitinib.
Findings: PDL1was present in insulin-positive cells from twelve T1D individuals (6 living and 6 deceased donors)
but absent from insulin-deﬁcient islets or from the islets of six non-diabetic controls. Interferons-α and -γ, but
not interleukin-1β, induced PDL1 expression in vitro in human islet cells and EndoC-βH1 cells. Silencing of
STAT1 or STAT2 individually did not prevent interferon-α-induced PDL1, while blocking of JAKs – a proposed
therapeutic strategy for T1D – or IRF1 prevented PDL1 induction.
Interpretation: These ﬁndings indicate that PDL1 is expressed in beta cells from people with T1D, possibly to at-
tenuate the autoimmune assault, and that it is induced by both type I and II interferons via IRF1.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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CD2741. Introduction
The introduction of immune checkpoint inhibitors into clinical prac-
tice represents a major improvement for the treatment of advanced
cancers [1]. Antibodies targeting the programmed death receptor-1
(PD-1) and its ligand, programmed death-ligand 1 (PDL1) [2] arees Research, Medical Faculty,
k@ulb.ac.be (D.L. Eizirik).
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betes and Associated Metabolic
. This is an open access article underparticularly efﬁcacious. These reagents counteract the normally inhibi-
tory effects of PDL1 (often up-regulated on tumor cells) on PD-1-ex-
pressing cytotoxic T-cells, thereby facilitating the targeting of the
tumor cells by inﬁltrating lymphocytes.
PDL1 expression is induced by several proinﬂammatory stimuli in
cancer cells, particularly by interferons (IFNs), IL-1β, IL6, IL10, IL12,
IL17, TGF-β and TNFα [3]. The JAK/STAT-IRF1 pathway is the key regu-
lator of IFN-mediated PDL1 expression in melanoma cells [4], while NF-
κB activation is crucial for lipopolysaccharide (LPS)-induced PDL1 in
macrophages [5]. A type I interferon signature precedes the develop-
ment of autoimmunity in children genetically at risk for T1D [6] and
IFNα, a member of the type I IFN family, is expressed in human islets
from type 1 diabetic patients [7].
Immune checkpoints have physiological function, namely themain-
tenance of peripheral tolerance to self-antigens [8]. In accord with this,
nearly 15% of patients treated with immune checkpoint inhibitorsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Antibodies targeting PD-1 and its ligand PDL1 are used in cancer
immunotherapy but may lead to autoimmune diseases, including
type 1 diabetes (T1D). PDL1 expression is induced by several pro-
inflammatory stimuli in cancer cells, particularly by interferons
(IFNs), IL-1β, IL6, IL10, IL12, IL17, TGF-β and TNFα, and can
also be induced in human islets by IFNs. The PD-1-PDL1 system
is crucial to the preservation of tolerance to pancreatic beta cell
antigens and, if disrupted, immune-mediated beta cell loss might
proceed more quickly in genetically predisposed individuals.
Sources: Pubmed.
Search terms: PD-1; PDL1; cancer immunotherapy; endocrine au-
toimmune diseases; type 1 diabetes; pancreatic islets.
Added value of this study
We observed that PDL1 is present in insulin-positive cells from
twelve T1D individuals but absent from insulin-deficient islets or
from the islets of non-diabetic controls. Interferons-α and -γ, but
not interleukin-1β, induce PDL1 expression in vitro in human
beta cells. Silencing of STAT1 or STAT2 individually does not pre-
vent interferon-α-induced PDL1, while blocking of JAKs – a pro-
posed therapeutic strategy for T1D – or IRF1 prevents PDL1
induction. These findings indicate that PDL1 is expressed in beta
cells from peoplewith T1D, possibly to attenuate the autoimmune
assault, and that it is induced by both type I and II interferons via
IRF1.
Implications of all the available evidence
The present findings suggest the presence of an active dialog be-
tween beta cells and immunecells during insulitis,mediatedby the
release of pro- and anti-inflammatory cytokines by both immune
cells and beta cells and by “danger signals” released from stressed
or dying beta cells. It is usually assumed that this dialog has a
largely negative outcome for the beta cells, but the present data
suggest that two of the cytokines that are locally released during
insulitis, namely IFNα and IFNγ, up-regulate PDL1 expression in
human beta cells. Up-regulation of this immune checkpoint inhib-
itor may delay progression of human T1D, and may explain why
beta cell destruction is heterogeneous in the pancreas if, for exam-
ple, some beta cells express PDL1 to a greater extent than others.
New drugs should be developed to prevent IFNα-induced pro-
inflammatory effects, i.e. HLA class I up-regulation, chemokine
production and ER stress, while preserving up-regulation of the
protective PDL1. Our previous and present observations that inhi-
bition of STAT2 prevents IFNα-induced HLA class I but not PDL1
up-regulation suggest that this may be feasible.
368 M.L. Colli et al. / EBioMedicine 36 (2018) 367–375develop endocrine autoimmune diseases [9]. These individuals are
prone to autoimmune diseases affecting the hypophysis, thyroid, adre-
nals and pancreatic beta cells [10], in the latter case, leading to type 1 di-
abetes [11]. In line with this, inhibition of PD-1-PDL1 signaling
accelerates diabetes in NOD mice [12], while overexpression of PDL1
in beta cells prevents diabetes in these animals [13]. When coupled
with induction of islet neogenesis in the liver, this can revert hypergly-
cemia [14].
Such ﬁndings indicate that the PD-1-PDL1 system is crucial to the
preservation of tolerance to pancreatic beta cell antigens and that, if
disrupted, immune-mediated beta cell lossmight proceedmore quickly
in genetically predisposed individuals. It remains to be deﬁned,however, whether PDL1 is expressed in the pancreatic islets of people
with type 1 diabetes and, if that is the case, which factors mediate its
up-regulation and the signaling pathways involved.
2. Materials and methods
2.1. Tissue
Formalin-ﬁxed parafﬁn embedded pancreatic sections from the Exe-
ter Archival Diabetes Biobank (EADB; http://foulis.vub.ac.be/) or from
the DiViD biopsy study of living donors with recent-onset type 1 diabe-
tes [15]were studied. These comprised samples from6 non-diabetic pa-
tients (age range: 4–58 years) and 12 individuals with type 1 diabetes,
in a total of 18 independent subjects studied (Table S1). All samples
were studied with full ethical approval and following the adequate
reporting standards for human studies.
2.2. Immunoﬂuorescence
After standard dewaxing and rehydration, samples were subjected
to heat–induced epitope retrieval (HIER) in Universal Buffer (Abcam,
UK) then probed in a sequential manner with three different antibodies
(Table S2). The relevant antigen-antibody complexes were detected
using secondary antibodies conjugated with ﬂuorescent dyes (Alexa
Fluor™ anti-mouse 555, anti-rabbit TSA 488, anti-guinea pig 647)
(Invitrogen, Paisley, U.K). Cell nuclei were stained with DAPI. After
mounting, images were captured with a Leica AF6000 microscope
(Leica, Milton Keynes, UK) and processed using the standard LASX
Leica software platform. For the analysis of the immunostaining proﬁle,
two independent observers assessed the presence or absence and inten-
sity of staining for each antigen (insulin and PDL1) starting from a posi-
tion in which the immunostaining is negative (for instance, most
control islets are scored as zero because they do not stain positively
for PDL1; see Results) until cases in which most islets were positive
and with intense staining (scored as 3). We have minimised bias by en-
suring that each observer was blind to the status of the sample (group
assignment and outcome assessment) and then comparing the scoring
among the observers in a post hoc analysis. In cases where doubt
persisted, two additional observers were invited to score the samples
in a similarly blinded manner to verify the initial observations. The
values shown describe the mean ± SEM of the two observers and the
“n” represents independent biological data.
2.3. Culture of human EndoC-βH1 cells and human islets, and cell
treatments
The human beta cell line EndoC-βH1 (kindly provided by Dr. R.
Scharfmann, University of Paris, France [16], RRID:CVCL_L909) was cul-
tured in Matrigel-ﬁbronectin-coated plates as described [17]. Human
islet isolation [18] from 10 non-diabetic organ donors (Table S3) was
performed in accordance with the local Ethical Committee in Pisa,
Italy. After arrival in Brussels, the islets were dispersed and cultured as
described in [17]. All experiments shown with EndoC-βH1 cells or
human islet cells (indicated as “n” in the ﬁgures) refer to independent
biological samples.
Where indicated, cells were pre-treated with human IFNα
(PeproTech Inc., Rocky Hill, NJ, RRID:SCR_006802) 2000 U/ml, human
IFNγ (PeproTech Inc., RRID:SCR_006802) 1000 U/ml or human IL-1β
(R&D Systems, Abingdon, UK, RRID:SCR_006140) 50 U/ml [17]. In
some experiments cells were pre-treated for 1 h with ruxolitinib 1 or
4 μM (Selleckchem, Germany, RRID:SCR_003823) [19] and the drug
maintained in the medium during the subsequent exposure to cyto-
kines, or transfected with an unspeciﬁc control siRNA (siCTL) or siRNAs
targeting STAT1 or STAT2 (these siRNAs have been previously validated
by us, andwere used at similar concentrations (30 nM) and transfection
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to cytokines. The sequences of the siRNAs used are listed in Table S4.
2.4. Real-time PCR, Western blot and ﬂow cytometry analysis
Poly(A) + mRNA was isolated using the Dynabeads mRNA DIRECT
kit (Invitrogen) following the manufacturer's instructions, and reverse
transcribed as described [17]. Quantiﬁcation by real-time PCR was car-
ried out using SYBR Green. Gene expression values were corrected by
the housekeeping gene β-actin, as its expression is not affected by the
experimental conditions used in this study [17]. The primers used are
listed in Table S4.
ForWestern blot cells were lysed with Laemmli buffer. Total protein
was resolved by 10% SDS-PAGE gel and then transferred to a nitrocellu-
lose membrane. Immunoblot analysis was performed with the speciﬁc
antibodies as indicated. Peroxidase-conjugated antibodies were used
as secondary antibodies (list of antibodies in the Key Resources Table).
Chemiluminescent substrate (SuperSignal West Femto, Thermo Scien-
tiﬁc, Chicago, USA) was used to detect immunoreactive bands using a
Bio-Rad chemi DocTM XRS+ system (Bio-Rad laboratories). Densito-
metric analysis of the bands was performed using the ImageLab soft-
ware (Bio-Rad laboratories), and the values were normalized by the
housekeeping protein α-tubulin and then by the highest value of each
experiment considered as 1.
Flow cytometry analysis was performed as previously described
[17], in brief, EndoC-βH1 cells were plated in 24-well plates and ex-
posed to IFNα for 24 h. After that, cells were incubated with rabbit
monoclonal anti-PDL1 antibody [28–8] (1:250) for 2 h at 4 °C, without
permeabilisation, and subsequently with secondary antibody conju-
gated with ﬂuorescent dyes for 1 h (1:500) (Alexa Fluor™ anti-rabbit
647) before performing ﬂow cytometry analysis (FACSCanto; BD Biosci-
ences, San Jose, CA, USA). Analysis was performed using FACSDiva soft-
ware version 1.0 (BD Biosciences, San Jose, CA, USA). For the
experiments with co-stain for PDL1 plus insulin, human islets were in-
cubated with rabbit monoclonal anti-PDL1 antibody [28–8] (Abcam)
(1:250) for 2 h at 4 °C, without permeabilisation, and subsequently
with secondary antibody conjugated with ﬂuorescent dyes for 1 h
(1:500) (Alexa Fluor™ anti-rabbit 647). After that cells were ﬁxed
with paraformaldehyde 4%, permeabilized with saponin 1% and incu-
bated with guinea pig anti-insulin (1:200) (DAKO, #A0564) and subse-
quently with secondary antibody conjugated with ﬂuorescent dyes for
1 h (1:500) (Alexa Fluor™ anti-guinea pig 488) before performing
ﬂow cytometry analysis (FACSCanto; BD Biosciences, San Jose, CA, USA).
2.5. Promoter studies
EndoC-βH1 cells or dispersed human islets were transfected with
plasmid constructs containing the ﬁreﬂy luciferase gene under the con-
trol of the human PDL1 promoter presenting or not a site-directed mu-
tagenesis deletion in the IRF1 binding site (a kind gift from Prof. A. Ribas
(University of California, UCLA, USA) [4]) using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer instruc-
tions. Twelve hours later, cells were exposed to IFNα (2000 U/ml) or
IFNγ (1000 U/ml) for 24 h. Luciferase activities were assayed using
the Dual-Luciferase Reporter Assay System (Promega, Madison, WI,
USA). Values were corrected for the luciferase activity of the internal
control plasmid, pRL-CMV, and shown as fold induction compared
with untreated cells. In some experiments these constructs were co-
transfectedwith siControl, siIRF1#1 or #2, in the same conditions as de-
scribed above.
2.6. Statistical analysis
Data are expressed as means ± SEM. A signiﬁcant difference be-
tween experimental conditions was assessed by one-way or two-ways
ANOVA followed by Bonferroni correction for multiple comparisonsusing the GraphPad Prism program version 6.0 (www.graphpad.com).
Results with p b .05 were considered statistically signiﬁcant.
3. Results
3.1. PDL1 expression is elevated in the insulin-containing islets (ICI) of indi-
viduals with type 1 diabetes
Initially we assessed the expression of PDL1 in the islets of both peo-
ple with type 1 diabetes (3 children and 3 adults) along with age-
matched controls. PDL1 immunostainingwas absent (and consequently
scored as zero) or, at best, observed as very weak in a few islets of non-
diabetic individuals (Fig. 1A, upper panels; mean score 0.25) but was
seen clearly in those with type 1 diabetes (Fig. 1A, middle panels;
mean score 1.8, i.e. N7-fold higher than in non-diabetic individuals).
The up-regulation of PDL1 was detected most readily in beta cells
(Figs. 1A and B) although occasional alpha cells also appeared
immunopositive for PDL1 (Fig. 1A). Positive immunostaining was not
seen in insulin-deﬁcient islets (Fig. 1A, lower panels). Scoring of islet
PDL1 and insulin expression by two independent observers (unaware
of sample identity) based on the intensity of immunostaining (0 to
3) in a large number of islets from each of the patient groups conﬁrmed
these observations (Fig. 1C). In non-diabetic individuals, most islets
(70%) were negative for PDL1 with only 15 of 50 (30%) showing evi-
dence of very weak expression. By contrast, among the Exeter Archival
Diabetes Biobank (EADB) type 1 diabetes cases, 40 of 42 (95%) of the
insulin-containing islets were clearly immunopositive for PDL1. All
T1D insulin-deﬁcient islets (n= 18) scored 0.
PDL1mRNA expression was also 5–8 higher in islets of a relatively
recent-onset T1D individual as compared to the islets of a long-lasting
T1D individual and three healthy donors (Fig. S1A) [20]. On the other
hand, there was no increase in PDL1 expression in islets from individ-
uals with impaired glucose tolerance (IGT) or type 2 diabetes (T2D)
[21] (Fig. S1B) or in human islets exposed in vitro to the metabolic
stressor palmitate [22] (Fig. S1C). Thus, PDL1 expression is increased
during insulitis but is not modulated by dysglycemia and metabolic
stressors related to T2D.
3.2. Interferons are the main regulators of PDL1 expression in human pan-
creatic beta cells
IFNα and IFNγ, but not IL-1β, induced PDL1 mRNA expression in
EndoC-βH1 cells (Fig. 2A). PDL1 induction by both IFNs was of similar
magnitude, which is in line with the observed similar expression of
the receptors for IFNα and IFNγ in both EndoC-βH1 cells (Fig. S1D)
and human islets (Fig. S1E). We focused the subsequent experiments
on IFNα, which plays a key role in early insulitis [17]. IFNα induced
both PDL1 mRNA and protein expression in EndoC-βH1 cells (Figs. 2A
and C) and human islet cells (Figs. 2B and D), and led to a 2.8-fold in-
crease in cell surface expression of PDL1 in EndoC-βH1 cells, as shown
by ﬂow cytometry (Figs. 2E and F).
3.3. Inhibition of JAK1 decreases interferon-α-induced PDL1 expression
Inhibition of JAK1 (a key kinase for the signal transduction down-
stream of the IFNα receptor) by two speciﬁc siRNAs (Figs. 3A to D) re-
duced by 70% JAK1 expression at the mRNA (Fig. 3A) and protein
levels (Fig. 3C) and led to a 55% reduction in interferon-induced PDL1
mRNA (Fig. 3B) and protein PDL1 expression (Fig. 3D). This partial inhi-
bition in IFNα-mediated PDL1 induction after JAK1 silencing could be
due to a second kinase, Tyk2, also involved in the downstream signaling
of the type I interferon receptor [23] and/or to the fact that JAK1 silenc-
ing was only partial. To evaluate this, we used ruxolitinib, an FDA-
approved JAK kinase inhibitor [24], which promoted a dose-
dependent decrease in IFNα-induced PDL1mRNA expression (Fig. 3E),
and completely abolished PDL1mRNA expression (Fig. 3E) and its cell
Fig. 1. PDL1 expression is elevated in the insulin-containing islets (ICI) of individuals with type 1 diabetes, but not in insulin-deﬁcient islets (IDI) or in islets from individuals without
diabetes. (A) Immunostaining of PDL1 alone (green; left panel), PDL1 (green) and glucagon (red; middle panel) or PDL1 (green) glucagon (red) and insulin (light blue; right panel) is
shown in representative islets from individuals without diabetes (upper panels, A) and those with type 1 diabetes (middle and lower panels). Scale bar 20 μm. (B) Higher
magniﬁcation image demonstrating that PDL1 (green) is localized in beta cells (insulin; light blue). (C) Scoring of PDL1 and insulin expression (scale of 0–3; as judged by independent
observers) in islets from individuals without diabetes (green circle; n = 42 across 6 cases); insulin-containing islets (red circle; n = 50 across 6 cases) and insulin deﬁcient islets (blue
circle; n = 18, across 6 cases) from type 1 diabetes. The mean values ± SEM of the scores are shown.
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ilar to EndoC-βH1 cells, the pretreatment of human islets with
ruxolitinib prevented the IFNα-induced signaling pathways (Fig. 3H)
leading to severe inhibition in PDL1mRNA (Fig. 3G) and protein expres-
sion (Figs. 3H and I), which was conﬁrmed by a decrease in global PDL1
positive (+) cells or PDL1+ and insulin+ cells as evaluated by ﬂow cy-
tometry (Figs. 3J and 3K). These results conﬁrm the importance of JAK1
for IFNα-mediated PDL1 regulation.
3.4. Interferon-α-induced PDL1 expression depends on STAT1 and STAT2
activity
A time-course analysis of the key transcription factors induced by
IFN showed a very early and marked activation of STAT1 and STAT2
(with peak at 0.5 h), followed by IRF1 activation (peak by 2 h) and
then PDL1 up-regulation, starting at 8 h (Figs. S2A to F). STAT2 is a cru-
cial transcription factor mediating IFNα-induced HLA class I expression
and ER stress in human beta cells [17]. Surprisingly, STAT2 knockdown
(KD) (Fig. 4C and S3B) induced a paradoxical effect, namely a clear trend
for increased PDL1 expression (Fig. 4D), present in each individual ex-
periment (not shown). Inhibition of STAT1 (Fig. 4A and S3A) led to an
even more marked (N5-fold) paradoxical up-regulation of IFNα-
induced PDL1 up-regulation at mRNA (Fig. 4B) and protein level
(Fig. S3C). On the other hand, STAT1 inhibition (Fig. S3E) signiﬁcantly
decreased IFNγ-induced PDL1 expression (Fig. S3F), which is in line
with the key role for this transcription factor in IFNγ signaling in beta
cells [25]. STAT1 leads to STAT2 up-regulation (and vice versa) follow-
ing IFNα exposure [17], a ﬁnding conﬁrmed in the present study
(Fig. S3D). To investigate whether this compensatory mechanism may
explain the presently observed paradoxical effect of STAT1 and STAT2
KD on IFNα-induced PDL1 expression (Fig. 4B and 4D), we knockeddown STAT1 and STAT2 in parallel (Figs. 4E and F) and observed that
this double KD of STAT1/2 reduced IFNα-induced PDL1 mRNA
(Fig. 4G) and protein (Fig. S3C) expression by 80%. These ﬁndings
were conﬁrmed in primary human islets (Fig. S4A to C).
IRF1, a key downstream transcription factor regulated by STATs in
beta cells [25], was up-regulated several fold by IFNα (Fig. S2E). Trans-
fection of EndoC-βH1 cells and dispersed human islets with a luciferase
reporter construct of the human PDL1 promoter presenting or not a de-
letion of the IRF1 binding site [4] showed that IFNα induced a N 8-fold
increase in PDL1 promoter activity, while IRF1 deletion abolished this
effect (Figs. 4H and S4D); similar ﬁndings were obtained with IFNγ
(Fig. S3G). Co-transfection of EndoC-βH1 cells with two independent
siRNAs silencing IRF1 (Fig. 4I) plus the wild type PDL1 promoter par-
tially (40–50%) decreased PDL1 promoter activity (Fig. 4J). The IRF1
knockdown (Fig. S4E) in human islets also decreased PDL1 protein ex-
pression induced by IFNα (Fig. S4F).
We next evaluated the correlation between PDL1 and IRF1 expres-
sion in human pancreas from people with T1D. IRF1 was not present
in the islets of any control sample studied (not shown) but was mark-
edly up-regulated in certain islet cells in T1D (Fig. 4K). PDL1 was fre-
quently increased in concert with IRF1 immunopositivity (Fig. 4K)
although the two antigens were not always localized within the same
islet cells. We did not ﬁnd any islets where PDL1 expression occurred
in the absence of IRF1. To study these relationships further, 15 insulin-
containing islets were selected at random from each of the 6 DiViD
type 1 diabetes cases [15] (Table S1) and scored by two independent ob-
servers for expression of either PDL1 or IRF1 (Fig. 4L). Triple–staining
was employed to label insulin, PDL1 and IRF1 and only insulin-
containing islets were scored. IRF1 was present in 58 of 90 (64%) islet
cells; most of which were beta cells. In 4 of the cases studied (DiViD
1,3,4 & 5) the majority of the IRF1 immunopositive islets (47 of 60
Fig. 2. Interferons type I and II, but not interleukin-1β, up-regulate PDL1mRNA and protein expression in human pancreatic beta cells. EndoC-βH1 cells (A, C, E and F) and primary human
islets (B and D)were exposed to interferon-α (IFNα, 2000 U/ml), interferon-γ (IFNγ, 1000 U/ml) or interleukin-1β (IL1β, 50 U/ml) for 24 h (A, C, D, E, F) for the indicated time points (B).
(A and B) PDL1mRNA expressionwas evaluated by real time RT-PCR. The valueswere normalized by the housekeeping gene beta-actin and are represented as fold induction compared to
non-treated control cells (NT) (n= 3–5, * p b .05, ** p b .01, *** p b .001, ANOVAwith Bonferroni correction). (C and D) PDL1 protein expression was determined byWestern blot (upper
part of the ﬁgure), quantiﬁed by densitometry and normalized by the housekeeping proteinα-tubulin and then by the highest value of each experiment considered as 1 (n= 6–7, ** p b
.01, *** p b .001, paired t-test). (E and F) PDL1 cell surface expression was quantiﬁed by ﬂow cytometry analysis at baseline or after exposure to IFNα. (E) Histograms represent changes in
mean ﬂuorescence intensity. (F) The geometric mean of the mean ﬂuorescence intensity was quantiﬁed at baseline and after exposure to IFNα (n= 3, * p b .05, paired t-test). The mean
values ± SEM are shown.
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Fig. 3. JAK1 blocking by siRNAs or a chemical inhibitor decreases interferon-α-induced PDL1 expression. (A to C) EndoC-βH1 cells were transfected with an unspeciﬁc control siRNA
(siCTL) or two independent siRNAs targeting JAK1 (siJAK1 #1 and #2). After 48 h of recovery, the cells were exposed or not to interferon-α (IFNα, 2000 U/ml) for 24 h. Then, JAK1
and PDL1 mRNA and protein levels were determined by real time RT-PCR or Western blot, respectively. (n = 4–7, ** p b .01, *** p b .001, ANOVA with Bonferroni correction). EndoC-
βH1 cells (E and F) or human islets (G to K) were pretreated for 1 h with the JAK1 inhibitor ruxolitinib at the indicated doses or the vehicle DMSO (control) and then exposed to IFNα
for 24 h. (E and G) PDL1 mRNA expression was evaluated by real time RT-PCR. The values were normalized by the housekeeping gene beta-actin and are represented as fold induction
compared to non-treated cells (NT) (n = 3–5, *** p b .001, ANOVA with Bonferroni correction). (H) Phosphorylated STAT1, phosphorylated STAT2, PDL1 and α-tubulin protein
expression were determined by Western blot (image representative of three independent experiments). (F, I, J and K). IFNα-induced PDL1 cell surface expression was measured by
ﬂow cytometry in the presence or not of chemical JAK inhibition. (I) Histograms represent changes in mean ﬂuorescence intensity. (J and K) The frequency of PDL1 positive cells was
quantiﬁed in the entire islet population (J, n= 3) or among the insulin positive cells only (K, n= 2) (*** p b .001, ANOVAwith Bonferroni correction). Themean values± SEM are shown.
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& 6) a lower proportion were positive for both antigens (5 of 30 islets
(17%)). Among all 6 cases, only 6 of 90 (6.7%) islets expressed IRF1
alone and none stained only for PDL1. Importantly, there was a clear
correlation between insulitis (as judged by inﬁltration of CD8+ T-
cells) and expression of PDL1/IRF1 (Fig. 4M).4. Discussion
We presently show that PDL1 is expressed in pancreatic islets from
T1D patients. Expression is seen most clearly in pancreatic beta cells.
PDL1 was present in both young and older individuals with T1D, but
was not found in insulin-deﬁcient islets where beta cells had been
374 M.L. Colli et al. / EBioMedicine 36 (2018) 367–375destroyed. This could imply that PDL1 expression had been lost from
such islets in parallel with the loss of beta cells. It cannot be excluded,
however, that their early demise may have resulted from a failure to
up-regulate PDL1 effectively during the inﬂammatory assault.
PDL1 up-regulation in beta cells appears to occur as a response to the
inﬂammatory process associated with T1D, as it was not detected in the
islets of non-diabetic individuals and it correlated with pancreatic islets
CD8+ T-cell inﬁltration (Fig. 4M). In vitro studies using human islets
and human insulin-producing EndoC-βH1 cells indicate that PDL1 is in-
duced by type I and II IFNs, but not by IL-1β. Surprisingly, and in contrast
to ﬁndings with cancer cells [4], the regulation of IFNα-induced PDL1
expression in beta cells is not dependent of STAT1 or STAT2 alone, but
required both STATs (present data) and their downstream transcription
factor IRF1. Of note, the present data also indicate that the early steps of
IFNα signaling, via JAK activation, are essential for IFNα-induced PDL1
expression in beta cells.
There is probably an active dialog between beta cells and immune
cells during insulitis, mediated by the release of pro- and anti-
inﬂammatory cytokines by both immune cells and beta cells and by
“danger signals” released from stressed or dying beta cells [26]. This di-
alog is triggered/modulated by putative environmental signals and the
genetic background of the affected individuals [26,27]. It is usually as-
sumed that the dialog has a largely negative outcome for the beta
cells, but the present data suggest a more nuanced picture. Thus, two
of the cytokines that may be elaborated during insulitis, namely IFNα
(that probably plays an important role at the early stages of insulitis, re-
lated to local activation of innate immunity) and IFNγ (that probably
plays a more important role at later stages, related to adaptive immu-
nity), up-regulate PDL1 expression in human beta cells; these ﬁndings
were corroborated by a very recent study by another group [28]. This
up-regulation of an immune checkpoint inhibitor is probably of impor-
tance to delay progression of human T1D, andmay explainwhy beta cell
destruction is heterogeneous in the pancreas if, for example, some beta
cells express PDL1 to a greater extent than others. This possibility is re-
inforced by the present ﬁndings that some, but not all, beta cells in the
IFNα-treated islets or in histology samples from diabetic patients ex-
press PDL1. It is thus conceivable that beta cells with high PDL1 expres-
sion are able to resist T-cell mediated apoptosis over longer periods and
thereby persist in the face of the immune assault, as is the case for PDL1-
expressing cancer cells [29]. Indeed, there is an increased expression of
PDL1 in long-term surviving beta cells under autoimmune attack in
NOD mice [30]. The fact that anticancer therapies that block PD-1-
PDL1 trigger T1D in some individuals [11] supports the concept that
PDL1 provides protection to beta cells during insulitis, thereby enabling
these individuals to evade or at least to delay the onset of diabetes.
However, once PDL1 signaling is interrupted, the immune assault is in-
tensiﬁed and accelerates beta cell loss. This possibility also bears rele-
vance for the potential use of JAK inhibitors as anti-diabetic agents.
Such drugs are currently under evaluation for the therapy of rheuma-
toid arthritis and various other autoimmune diseases [31,32] and have
been suggested by us [19] and others [33] as potential therapies for
T1D. The present results, and recent data showing that blockade of
type I IFNs can either trigger or prevent diabetes depending on the
stage of the autoimmune process in diabetes-prone NOD mice [34],Fig. 4. Combined STAT1 plus 2 or IRF1 silencing decrease interferon-α-induced PDL1 expression
STAT1 (siSTAT1) and/or STAT2 (siSTAT2). After 48 h of recovery, the cells were exposed or not
PDL1 expression (B, D, G)were determined by real time RT-PCR. The valueswere normalized by
treated cells (NT) (n= 3–6, * p b .05, ** p b .01, *** p b .001, ANOVAwith Bonferroni correction)
wild type human PDL1 promoter or the same construct presenting a deletion in the IRF1 bindin
for 24 h and luciferase activity was assayed. The valueswere corrected for the activity of the inte
relation to non-treated cells (NT) considered as 1 (n=4, ** p b .01, *** p b .001, ANOVAwith Bo
or two independent siRNAs targeting IRF1 (siIRF1 #1 and #2) plus the wild type PDL1 promo
luciferase activity was assayed (J). The knockdown efﬁciency (I) was determined by real time
PDL1 (green), IRF1 (red), insulin (light blue) and nuclei (dapi; dark blue) in the islets of an in
at higher magniﬁcation. (L) 15 islets were selected at random from each of 6 individuals wi
immunonegative for both PDL1 and IRF1, or were immunopositive for PDL1 alone, IRF1 alone
and IRF1 was scored in relation to islet inﬂammation measured as the mean number of CD8+raise concerns about this strategy. Thus, a careful evaluation will be re-
quired to determine the appropriate moment in the natural history of
human T1D to introduce JAK inhibitors or other agents designed to dis-
rupt IFN signaling. Ideally, new drugs should be developed to prevent
IFNα-induced HLA class I up-regulation and ER stress [17,19] without
preventing the protective PDL1 up-regulation. The observation that in-
hibition of STAT2, for instance, prevents IFNα-induced HLA class I up-
regulation [17] but not PDL1 up-regulation (present data) implies that
this may be feasible.
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